Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8941467rdf:typepubmed:Citationlld:pubmed
pubmed-article:8941467lifeskim:mentionsumls-concept:C0011860lld:lifeskim
pubmed-article:8941467lifeskim:mentionsumls-concept:C0596382lld:lifeskim
pubmed-article:8941467lifeskim:mentionsumls-concept:C0035309lld:lifeskim
pubmed-article:8941467lifeskim:mentionsumls-concept:C0009566lld:lifeskim
pubmed-article:8941467lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:8941467lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:8941467lifeskim:mentionsumls-concept:C0015730lld:lifeskim
pubmed-article:8941467pubmed:issue12lld:pubmed
pubmed-article:8941467pubmed:dateCreated1997-3-7lld:pubmed
pubmed-article:8941467pubmed:abstractTextThe main goal of the study of 153 male veterans was to determine whether a statistically and clinically significant difference in HbA1c could be achieved between a standard therapy and an intensively treated group of patients with type II diabetes. A second major goal was to assess the feasibility of collecting reliable high-quality endpoint data, including microvascular and macrovascular events. Retinopathy was defined as a key microvascular endpoint.lld:pubmed
pubmed-article:8941467pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8941467pubmed:languageenglld:pubmed
pubmed-article:8941467pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8941467pubmed:citationSubsetIMlld:pubmed
pubmed-article:8941467pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8941467pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8941467pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8941467pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8941467pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8941467pubmed:statusMEDLINElld:pubmed
pubmed-article:8941467pubmed:monthDeclld:pubmed
pubmed-article:8941467pubmed:issn0149-5992lld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:AbrairaCClld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:LevinSSlld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:ComstockJJlld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:LeeH SHSlld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:HendersonW...lld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:KleinRRlld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:NuttallFFlld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:ColwellJJlld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:EmanueleNNlld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:SawinCClld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:SilbertCClld:pubmed
pubmed-article:8941467pubmed:authorpubmed-author:Johnson-Nagel...lld:pubmed
pubmed-article:8941467pubmed:issnTypePrintlld:pubmed
pubmed-article:8941467pubmed:volume19lld:pubmed
pubmed-article:8941467pubmed:ownerNLMlld:pubmed
pubmed-article:8941467pubmed:authorsCompleteYlld:pubmed
pubmed-article:8941467pubmed:pagination1375-81lld:pubmed
pubmed-article:8941467pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:meshHeadingpubmed-meshheading:8941467-...lld:pubmed
pubmed-article:8941467pubmed:year1996lld:pubmed
pubmed-article:8941467pubmed:articleTitleEvaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.lld:pubmed
pubmed-article:8941467pubmed:affiliationHines VA Hospital, Endocrinology/Diabetes Section (11IA), IL 60141-5000, USA.lld:pubmed
pubmed-article:8941467pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8941467pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8941467pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:8941467pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8941467lld:pubmed